Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, Troncone C, Fontana A, Ientile V, Gini R, Santoro D, Santarpia M, Genazzani A, Uomo I, Pastorello M, Addario WS, Scondotto S, Cananzi P, Caputi AP, Trifirò G. Ingrasciotta Y, et al. Among authors: giorgianni f. BioDrugs. 2015 Aug;29(4):275-84. doi: 10.1007/s40259-015-0132-7. BioDrugs. 2015. PMID: 26169209 Free PMC article.
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
Ingrasciotta Y, Giorgianni F, Marcianò I, Bolcato J, Pirolo R, Chinellato A, Ientile V, Santoro D, Genazzani AA, Alibrandi A, Fontana A, Caputi AP, Trifirò G. Ingrasciotta Y, et al. Among authors: giorgianni f. PLoS One. 2016 May 17;11(5):e0155805. doi: 10.1371/journal.pone.0155805. eCollection 2016. PLoS One. 2016. PMID: 27187174 Free PMC article.
The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy.
Ingrasciotta Y, Sultana J, Giorgianni F, Caputi AP, Arcoraci V, Tari DU, Linguiti C, Perrotta M, Nucita A, Pellegrini F, Fontana A, Cavagna L, Santoro D, Trifirò G. Ingrasciotta Y, et al. Among authors: giorgianni f. PLoS One. 2014 Feb 18;9(2):e89072. doi: 10.1371/journal.pone.0089072. eCollection 2014. PLoS One. 2014. PMID: 24558471 Free PMC article.
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
Marcianò I, Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Di Giorgio A, Manna S, Ientile V, Gini R, Santarpia M, Genazzani AA, Uomo I, Pastorello M, Pollina Addario SW, Scondotto S, Cananzi P, Da Cas R, Traversa G, Rossi M, Sottosanti L, Caputi AP, Trifirò G. Marcianò I, et al. Among authors: giorgianni f. BioDrugs. 2016 Aug;30(4):295-306. doi: 10.1007/s40259-016-0175-4. BioDrugs. 2016. PMID: 27138636
Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014.
Marcianò I, Ingrasciotta Y, Giorgianni F, Ientile V, Chinellato A, Tari DU, Gini R, Cannavò S, Pastorello M, Scondotto S, Cananzi P, Traversa G, Trotta F, Belleudi V, Addis A, Trifirò G. Marcianò I, et al. Among authors: giorgianni f. Front Endocrinol (Lausanne). 2018 Mar 13;9:95. doi: 10.3389/fendo.2018.00095. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 29593655 Free PMC article.
96 results